| Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of … A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, S Lonardi, ... The Lancet Oncology 17 (6), 738-746, 2016 | 945 | 2016 |
| Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer G Siravegna, L Lazzari, G Crisafulli, A Sartore-Bianchi, B Mussolin, ... Cancer Cell 34 (1), 148-162. e7, 2018 | 136 | 2018 |
| HER2 Positivity Predicts Unresponsiveness to EGFR‐Targeted Treatment in Metastatic Colorectal Cancer A Sartore‐Bianchi, A Amatu, L Porcu, S Ghezzi, S Lonardi, F Leone, ... The oncologist 24 (10), 1395, 2019 | 124 | 2019 |
| Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial A Sartore-Bianchi, S Lonardi, C Martino, E Fenocchio, F Tosi, S Ghezzi, ... ESMO open 5 (5), e000911, 2020 | 111 | 2020 |
| Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial. S Siena, A Sartore-Bianchi, S Lonardi, L Trusolino, C Martino, ... Journal of Clinical Oncology 33 (15_suppl), 3508-3508, 2015 | 81 | 2015 |
| Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer F Tosi, A Sartore-Bianchi, S Lonardi, A Amatu, F Leone, S Ghezzi, ... Clinical Colorectal Cancer, 2020 | 69 | 2020 |
| Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III … R Ricotta, A Verrioli, S Ghezzi, L Porcu, A Grothey, A Falcone, ... ESMO open 1 (6), 2016 | 35 | 2016 |
| Liquid biopsy for rectal cancer: a systematic review D Massihnia, EG Pizzutilo, A Amatu, F Tosi, S Ghezzi, K Bencardino, ... Cancer treatment reviews 79, 101893, 2019 | 34 | 2019 |
| Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal … A Sartore-Bianchi, F Pietrantonio, A Amatu, M Milione, A Cassingena, ... European Journal of Cancer 71, 43-50, 2017 | 34 | 2017 |
| Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer: Long-term Results of Treatment With Trastuzumab and Lapatinib A Sartore-Bianchi, S Lonardi, M Aglietta, C Martino, F Ciardiello, ... JAMA oncology, 2020 | 25 | 2020 |
| Pooled analysis of clinical outcome of patients with chemorefractory metastatic colorectal cancer treated within phase I/II clinical studies based on individual biomarkers of … A Sartore-Bianchi, A Amatu, E Bonazzina, S Stabile, L Giannetta, G Cerea, ... Targeted oncology 12 (4), 525-533, 2017 | 16 | 2017 |
| Clinicopathological characteristics and HER2 status in metastatic colorectal cancer patients: Results of a diagnostic model development study. A Sartore-Bianchi, A Amatu, L Porcu, S Ghezzi, S Lonardi, F Bergamo, ... Journal of Clinical Oncology 36 (4_suppl), 581-581, 2018 | 4 | 2018 |
| Radiographic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer G Siravegna, L Lazzari, A Sartore-Bianchi, G Crisafulli, B Mussolin, ... Cancer Research 78 (13 Supplement), 2848-2848, 2018 | | 2018 |
